Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Immunovaccine Signs Agreement With National Research Council to Evaluate Carbohydrate-Based Vaccine

By Pharmaceutical Processing | October 18, 2010

Immunovaccine Inc. has entered into a collaborative research program with
the National Research Council Canada (NRC) to evaluate the efficacy of a
carbohydrate-based vaccine formulated in DepoVax, the company’s proprietary
vaccine delivery and enhancement platform. The antigen selected for this novel
vaccine formulation is a modified carbohydrate with the potential to be developed
into a meningococcal vaccine, as well as a therapeutic cancer vaccine.

The collaboration’s objective is to design a
carbohydrate-based vaccine, using the DepoVax formulation, that can produce
significant antibody levels specific to the carbohydrate target and capable of
neutralizing meningococci. The research will also evaluate the ability of the
carbohydrate-based vaccine candidate to kill cancer cells.

“This modified carbohydrate is unique because of its
potential utility as an antigen for both a bacterial vaccine and a therapeutic
cancer vaccine,” commented Marc Mansour, Ph.D., Immunovaccine’s Vice
President of R&D. “This is the first time we are incorporating a
carbohydrate antigen into our DepoVax platform to further demonstrate its
flexibility and versatility.”

Carbohydrate antigens are generally poorly immunogenic when
used in vaccines. In this study, the NRC and Immunovaccine will collaboratively
address this challenge. The NRC has developed a conjugation technology that
makes the carbohydrate more immunogenic for the immune system to generate an
antibody response. The immunogenicity of the modified carbohydrate is expected
to be enhanced by the DepoVax technology.

Immunovaccine’s DepoVax vaccine delivery and enhancement
technology will formulate the carbohydrate antigen into liposomes and then in
oil. This DepoVax delivery technology is a breakthrough in vaccine development
because it raises unusually strong and long-lasting humoral or cellular immune
responses. The ability for DepoVax to potentiate vaccines and deliver strong
results has been demonstrated in several animal models for infectious disease
and cancer.

 

 

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards